Table 3. Association between PD-L1 expression and other clinicopathological features.
| Clinicopathological parameters | No. of studies | No. of patients | Model | Pooled OR | 95% CI | P value | Heterogeneity | |
|---|---|---|---|---|---|---|---|---|
| I2 (%) | P value | |||||||
| Age, <60 vs. ≥60 years | 5 | 340 | Fixed | 1.44 | 0.84–2.46 | 0.18 | 0 | 0.83 |
| Gender, male vs. female | 3 | 188 | Fixed | 1.16 | 0.62–2.15 | 0.64 | 20 | 0.28 |
| B symptom, yes vs. no | 3 | 229 | Random | 1.16 | 0.42–3.14 | 0.78 | 62 | 0.07 |
| Stage, I–II vs. III–IV | 5 | 335 | Random | 0.64 | 0.31–1.32 | 0.23 | 51 | 0.09 |
| Lymph node invasion, none/regional vs. distant | 3 | 237 | Fixed | 1.82 | 0.92–3.59 | 0.08 | 25 | 0.26 |
| PINK, 0–1 vs. 2–4 | 3 | 236 | Random | 0.76 | 0.23–2.52 | 0.65 | 71 | 0.03 |
| Primary site, UAT vs. Not-UAT | 2 | 180 | Random | 1.12 | 0.35–3.56 | 0.85 | 65 | 0.09 |
| LDH level, elevated vs. normal | 4 | 298 | Random | 0.62 | 0.25–1.54 | 0.30 | 61 | 0.05 |
PD-L1, programmed cell death ligand 1; OR, odds ratio; CI, confidence interval; PINK, prognostic index of natural killer lymphoma; UAT, upper aerodigestive tract; LDH, lactic dehydrogenase.